clinical trials Archives - Healthcare Communications Network

Millennium Medical PublishingHighlights in Metastatic Breast Cancer From the European Society for Medical Oncology Virtual Congress 2020

This review and commentary from the ESMO Virtual Congress 2020 features a look at the following trials: ASCENT (sacituzumab govitecan-hziy), IMpassion130 (atezolizumab + nab-paclitaxel), IMpassion131 (first-line paclitaxel +/– atezolizumab), IPATunity130 (ipatasertib + paclitaxel), SEASTAR (rucaparib + sacituzumab govitecan), FLIPPER (fulvestrant/palbociclib), SOLAR-1 (alpelisib + fulvestrant), and FURVA (vandetanib + fulvestrant).

American Society of Clinical OncologyPlaying with Dynamite? A Cautious Assessment of TNT

In this article from the Journal of Clinical Oncology, the authors suggest the need for caution and well-conducted trials to systematically address the question of total neoadjuvant therapy (TNT) in rectal cancer, which can lead to overtreatment and unnecessary toxicity without a proven benefit. Despite some of its theoretical advantages, declaring TNT a new standard […]

HMP CommunicationsLetrozole Pre-Surgery Yields Drastic Biomarker Changes in ER+ DCIS

According to a study featured in the Journal of Clinical Oncology, pre-surgery letrozole led to significant imaging and biomarker changes in postmenopausal patients with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) in a phase 2 clinical trial.

Haymarket MediaDoes Clinician/Researcher Bias Contribute to Low Enrollment of Minorities in Cancer Clinical Trials?

This study in Cancer suggests the possibility, pointing to qualitative results of clinical trial principal investigators, research staff, referring clinicians, and cancer center leaders regarding their attitudes and experiences with enrolling minority patients in cancer clinical trials.